Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.
BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare in November 2019 for this indication.
